Sign in
CompletedNo phase

Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency

Key facts

Who runs it
Dr. Hatice Dönmez
Where
Türkiye1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
31 people enrolled
Started
15 Sept 2024
Ended
15 Jun 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Virtual reality video watching
  • Tablet video watching
Record updated
9 June 2026

Who can take part

Age
4 years to 11 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Being between the ages of 4-11
  • Being followed up with the diagnosis of Primary Immunodeficiency for at least 6 months
  • To accept participation in the study voluntarily
  • No additional chronic disease other than primary immunodeficiency

Who cannot take part

  • Organ failure is present
  • Having a mental deficiency
  • Having a disability to use VR Glasses
  • Children with fever (|>37.5 C0)
  • Children with severe dehydration

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

In this study, it is aimed to investigate the effect of virtual reality and tablet video viewing intervention on pain and fear levels and vital signs of children during peripheral venous catheter placement for intravenous immunoglobulin (IVIG) administration.

The 2 groups in the trial

  • Virtual reality groupTreatment being tested

    Treatment: Virtual reality video watching

  • Tablet groupExisting treatment, for comparison

    Treatment: Tablet video watching

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Virtual Reality on Pain and Fear Levels of Children With Primary Immunodeficiency Applying Intravenous Immunoglobulin During Intravenous Access: A Crossover Randomized Controlled Trial
Record updated
9 June 2026